Please login to the form below
Sandoz completes acquisition of GSK’s cephalosporin business
The acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network
AZ buys Caelum Biosciences for $500m
After AstraZeneca’s Alexion acquires all remaining equity in Caelum next week it will 'advance and accelerate' ongoing clinical development
Novo Nordisk settles US insulin pricing dispute for $100m
Novo Nordisk admits no liability or wrongdoing but will pay investors $100m to “avoid the burden, inherent risk and expense of further litigation”
Mysterious big pharma company eyes US biotech Acceleron
Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week
Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m
EU “still interested” in Valneva COVID vaccine despite UK snub
Negotiations between Valneva and the EU are “ongoing and advanced”, with its vaccine candidate VLA2001 touted as a potential booster shot in France
US orders 1.4 million more doses of Regeneron antibody cocktail
The new $2.9bn order increases the amount of Regeneron’s anti-COVID REGEN-COV purchased by the US government to nearly 3 million doses
Valneva shares fall as UK cancels COVID-19 vaccine order
The UK government has cancelled a supply agreement for French vaccine maker Valneva’s COVID candidate VLA2001 over an alleged breach of obligations.
AbbVie signs gene therapy deal in eye care
AbbVie and REGENXBIO have teamed up on RGX-314, a potential one-time gene therapy against two leading causes of blindness, wet AMD and diabetic retinopathy.
Health coverage across state lines
Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad
-
Standing out in a crowdCelltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars
-
The diseased organisationLike humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured
-
Roche expands infectious disease test portfolioPCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases
-
Roche bets on T-cell therapies with Adaptimmune deal
Genentech signs deal for five ‘off the shelf’ T-cell therapies and a personalised cell therapy platform in a deal potentially worth more than $3bn
-
PMGroup Worldwide Ltd and The Datateam Media Group welcome Samedan LtdSamedan joins PMGroup and PharmaTimes Media Ltd as part of The Datateam Media Group’s healthcare division
-
Pfizer to acquire Canadian immuno-oncology company Trillium in a deal worth $2.6bnThe deal will strengthen Pfizer’s oncology offering and follows an investment of $25m in Trillium made by Pfizer in January
-
Moderna’s stellar rise continues with revenues of $4.4bn in Q22021 revenue is expected to exceed $20bn, up from $803m in 2020, driven by revenue of $4.2bn from the sale of just under 200 million doses of the company's vaccine
-
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology dealThe deal will see Kumquat utilise its small molecule immune-oncology platform to discover novel clinical assets
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic
-
New hires at Ferring, Flexion and Immunocore The latest movers in pharma
-
New hires at Nanoform, Leo Pharma and CalliditasThe latest movers in pharma and biotech
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMOLatest movers in pharma and biotech
-
New hires at Mundipharma, Sinclair Pharma and Relay TherapeuticsLatest movers in pharma
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership teamThe latest industry movers
Latest sales appointments
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis
- bluebird bio provides update on 2seventy bio spin-off
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
